Longfei Zhang

This study shows that stabilizing the CHI3L1-Gal3BP complex with LZ6 improves the glioblastoma immune microenvironment and extends survival, both alone and when combined with PD-1 blockade.

The paper identifies CHI-DEL, a brain-penetrant CHI3L1 inhibitor, and validates its on-target effects using genetic rescue experiments and in vivo models of glioblastoma.

This paper identifies DELC2, a brain-penetrant CHI3L1 inhibitor, which reduces neuroinflammation and amyloid-β levels in Alzheimer's disease models.

This paper optimizes a CHI3L1 inhibitor, G721-0282, to improve potency and drug-like properties, demonstrating functional efficacy in reversing astrocytic dysfunction in Alzheimer's disease.

This paper identifies a small molecule inhibitor of CHI3L1, DEL-C1, which modulates neuroinflammation in Alzheimer's disease through multiple validated mechanisms.

This study identifies a CHI3L1 inhibitor, compound 9e, through structure-based virtual screening of a large chemical space, showing efficacy in a 3D GBM model.

This paper identifies Z17 as a selective CHI3L1 inhibitor that restores astrocytic function and mitigates neuroinflammation in Alzheimer's disease.

This study identifies small molecule inhibitors of CHI3L1 using SPR-based screening, showing functional activity in a GBM spheroid model.

This study identifies two small molecule CHI3L1 inhibitors using virtual screening and validates their activity in glioblastoma spheroids.

This study develops a TRIC-based HTS platform to identify CHI3L1-targeted small molecules, finding three compounds with varying binding and inhibitory effects on CHI3L1.

This paper identifies G28 as a potent CHI3L1 inhibitor through virtual screening, validates its binding affinity, and shows its efficacy in reducing GBM spheroid growth.

The paper designs and characterizes second-generation cyclic peptide LAG-3 inhibitors, identifying cyclic peptide 12 as the most effective with an IC50 of 4.45 µM.

This paper discovers small molecules targeting ICOS using ASMS screening and identifies key structural features for ICOS/ICOS-L inhibition.